New Page 1

Disclaimer
The present site is a portal. It is and shall not be held responsible, in any way, for any item sold or any transaction(s) and/or relating arrangements or dispute that might arise with the link chosen by the visitor. Nor will this site be responsible for any item in a country where it is banned, prohibited or illegal.

MOREOVER, THE PRESENT SITE IS INFORMAL, UNSCIENTIFIC, DRAFTED AND PUBLISHED BY A GURU, WITHOUT THE LEAST PRETENSE OF FORECASTING, RECOMMENDING OR SOLICITING ANYTHING WHATSOVER, OF ANY KIND. IT WILL, MOST OFTEN, JUST REFLECT WHAT THE WEBMASTER/SITE OWNER IS BUYING OR SELLING (LONG OR SHORT) IN OWN PORTFOLIO, WHICH, NEVERTHELESS IS ALWAYS DYNAMIC. DO NOT -- NEVER, EVER, TAKE AS AN AUTHORITY. KIND OF FOOL/DUMMY, ONLY.

IT IS YET IN ITS EXPERIMENTAL FIRST PHASE

Interested in How You Can Use A Stock Trading Robot to Earn $346.77 Per Week (Using $1000 Capital))?

Click Here!

First of all click here to: download Skype

GURU'S PERSONAL TOP CHOICE

Monday 28 April, 2008

Deemed by Guru extremely undervalued and possibly set to soar:

AFFYMETRIX (NASDAQ Symbol: AFFX)

Short sellers are buying back as evidenced by clicking on the link(s) below:

http://www.nasdaq.com/aspxcontent/shortinterests.aspx?mode=&kind=shortint&timeframe=&intraday=&charttype=&splits=&earnings=&movingaverage=&lowerstudy=&comparison=&index=&symbol=affx&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=&mkttype=&pathname=&page=short&selected=AFFX

WHAT INSIDERS ARE DOING:

http://www.secinfo.com/$/Search.asp?Find=affx

http://www.insidercow.com/history/company.jsp?company=affx&B1=Search%21

From March 31, 2008 to April 15, 2008, short interest dropped from 13,592,619 to 12,290,925

Other INFORMAL HIGHLIGHTS ABOUT AFFYMETRIX:

NASDAQ: http://finance.yahoo.com/q?s=affx

BLOOMBERG: http://www.bloomberg.com/apps/quote?ticker=affx

MARKET WATCH: http://www.marketwatch.com/quotes/affx/?dist=DNH_S

CHARTS:

http://bigcharts.marketwatch.com/interchart/interchart.asp?symb=affx&time=&freq=

Latest, Stunning Earnings Results:Click here

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2008

AFFYMETRIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State of incorporation)

0-28218
(Commission File Number)

77-0319159
(IRS Employer Identification No.)

3420 Central Expressway
Santa Clara, California 95051

(Address of principal executive offices) (Zip Code)

(408) 731-5000

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02

Results of Operations and Financial Condition.

On April 24, 2008, Affymetrix, Inc. (the “Company”) issued a press release announcing the Company’s operating results for the first quarter ended March 31, 2008. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information furnished under Item 2.02 of this Current Report on Form 8-K, including the exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into Affymetrix’ filings with the SEC under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01		Financial Statements and Exhibits

	(d)	Exhibits.


		Exhibit No.	Description

		99.1	Press Release dated April 24, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	AFFYMETRIX, INC.


	By:	/s/ John C. Batty
		Name: John C. Batty
		Title: Executive Vice President and Chief Financial
		Officer, Treasurer and Principal Financial Officer

Dated: April 24, 2008

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release dated April 24, 2008

EXHIBIT 99.1

FOR IMMEDIATE RELEASE

Contact:

Doug Farrell

Vice President of Investor Relations

408-731-5285

AFFYMETRIX REPORTS FIRST QUARTER 2008 RESULTS

Santa Clara, Calif. — April 24, 2008 — Affymetrix Inc., (Nasdaq: AFFX) today reported its operating results for the first quarter of 2008. Total revenue for the quarter was $169.6 million, including an intellectual property payment of $90 million, as compared to total revenue of $80.4 million in the first quarter of 2007.

Product revenue was $62.8 million, which consists of array and reagent revenue of $58.8 million and instrument revenue of $4.0 million. Service revenue was $8.4 million, and royalties and other revenue were $98.3 million for the first quarter of 2008. This compares to first quarter 2007 product revenue of $64.5 million. Service revenue was $8.8 million, and royalties and other revenue were $7.2 million for the first quarter of 2007. Affymetrix shipped 17 GeneChip^® systems in the quarter, bringing its cumulative systems shipped to 1,739 at the end of the first quarter.

The Company reported net income of approximately $46.3 million or $0.58 per diluted share in the first quarter of 2008, which includes a pretax restructuring charge of $13.9 million or $0.17 per diluted share, as compared to net loss of $4.0 million or $0.06 per diluted share in the first quarter of 2007, which included a pretax restructuring charge of $5.4 million or $0.08 per diluted share.

Cost of product sales was $26.0 million in the first quarter of 2008 compared to $22.1 million in the same period of 2007. Cost of services was $5.7 million compared to $6.4 million in the first quarter of 2007. Product gross margin was 59 percent in the first quarter of 2008 compared to 66 percent in the first quarter of 2007.

Operating expenses were $68.2 million for the first quarter of 2008, which includes restructuring charges of $13.9 million, as compared to $60.5 million in the first quarter of 2007, which includes restructuring charges of $5.4 million.

Financial Outlook for 2008

For fiscal 2008, the Company expects total revenue to be in the range of $490 million to $510 million. Total gross margin is expected to be approximately 69 percent, of which 7 percent is expected to be attributable to the one-time $90 million payment. The Company expects total operating expenses between $235 million to $240 million, including total restructuring of approximately $17 million.

Recent Highlights

DNA Analysis

· The Company signed an agreement with Avesthagen Limited, a leading biotechnology company based in Bangalore, India. Under the terms of the agreement, Affymetrix’ microarray technology will be used for The AVESTAGENOME Project™, a comprehensive genetic study of more than 60,000 Parsi individuals. The project will explore the genetic basis of longevity and create a genetic, genealogic and medical database of the Parsi-Zoroastrian population.

Copy Number

· Affymetrix announced the full commercial launch of its complete Cytogenetic Solution, which combines the high-density SNP Array 6.0 with a simple assay and intuitive software. The microarray-based solution provides cytogenetic researchers with an efficient and accurate method of detecting chromosomal abnormalities associated with congenital diseases such as autism and learning disabilities.

RNA Analysis

· The Company extended its Collaborations in Cancer Research Program (CCRP) to North America, forming an alliance between Affymetrix and 25 leading cancer researchers. The expansion builds on the success of the European CCRP, launched in April 2007. All of the researchers in the program are using Affymetrix’ SNP Array 6.0 and the Human Exon 1.0 ST Array to accelerate research on more than 10 types of cancer.

Drug Metabolism

· Affymetrix and Marshfield Clinic today announced that researchers at Marshfield Clinic used the Affymetrix Drug Metabolizing Enzymes and Transporters (DMET) solution to discover a genetic variation associated with an individual’s response to the drug warfarin. The study, “CYP4F2 genetic variant alters required warfarin dose,” was published by Blood Online. The results of the study could help reduce much of the serious adverse events caused by incorrect warfarin dosage and enable doctors to treat patients with a more effective, personalized form of medicine.

Corporate

· Affymetrix was named as one of the world’s top 50 most innovative companies by Fast Company magazine. Affymetrix was the only life sciences company to be recognized. Published in the March 2008 issue, the Company was commended for its work relating to the discovery of genetic variations and drug metabolism.

Affymetrix’ management team will host a conference call on April 24, 2008 at 2:00 p.m. PT to review its operating results for the first quarter of 2008. A live webcast can be accessed by visiting the Investor Relations section of the Company’s website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (866) 500-AFFX, international: (706) 643-2771.

A replay of this call will be available from 5:00 p.m. PT on April 24, 2008 until 8:00 p.m. PT on May 1, 2008 at the following numbers: domestic: (800) 642-1687, international: (706) 645-9291. The passcode for both replays is 43267963. An archived webcast of the conference call will be available under the Investor Relations section of the Company’s website at www.affymetrix.com.

About Affymetrix

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 12,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com.

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risk related to past and future acquisitions; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, risks associated with manufacturing and product development, including risks relating to the relocation of a substantial portion of our manufacturing to Singapore; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

PLEASE NOTE:

Affymetrix, the Affymetrix logo and GeneChip are trademarks owned or used by Affymetrix, Inc.

– Financial Charts to Follow –

AFFYMETRIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

(UNAUDITED)

	March 31, 2008			December 31, 2007
				(Note 1)
ASSETS:
Current assets:
Cash and cash equivalents	$	431,156		$	288,644
Restricted cash	4,000			—
Available-for-sale securities – short-term portion	158,842			205,718
Accounts receivable, net ($67 in 2008 and $389 in 2007 from Perlegen Sciences)	75,959			81,941
Inventories	51,787			42,912
Deferred tax assets – current portion	21,259			28,584
Notes receivable from employees – current portion	—			1,376
Prepaid expenses and other current assets	9,748			17,933
Total current assets	752,751			667,108
Available-for-sale securities – long-term portion	8,434			89,912
Property and equipment, net	129,786			143,884
Acquired technology rights, net	60,558			46,797
Goodwill	173,657			125,050
Deferred tax assets – long-term portion	34,069			18,426
Notes receivable from employees – long-term portion	133			487
Other assets	35,874			41,927
Total assets	$	1,195,262		$	1,133,591

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	53,859		$	61,543
Deferred revenue – current portion	17,438			22,498
Total current liabilities	71,297			84,041
Deferred revenue – long-term portion	3,838			3,922
Other long-term liabilities	10,135			10,971
Convertible notes	436,250			436,250
Stockholders’ equity:
Common stock	694			692
Additional paid-in capital	735,097			704,189
Accumulated other comprehensive income	171			1,998
Accumulated deficit	(62,220		)	(108,472		)
Total stockholders’ equity	673,742			598,407
Total liabilities and stockholders’ equity	$	1,195,262		$	1,133,591

Note 1:

The condensed consolidated balance sheet at December 31, 2007 has been derived from the audited consolidated financial statements at that date included in the Company’s Form 10-K for the fiscal year ended December 31, 2007.

AFFYMETRIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

(UNAUDITED)

	Three Months Ended
	March 31,
	2008			2007
Revenue
Product sales ($791 in 2008 and $6,678 in 2007 from Perlegen Sciences)	$	62,806		$	64,485
Services	8,420			8,757
Royalties and other revenue	98,349			7,193
Total revenue	169,575			80,435

Costs and expenses:
Cost of product sales ($442 in 2008 and $2,421 in 2007 from Perlegen Sciences)	25,977			22,145
Cost of services	5,678			6,406
Cost of royalties and other revenue	—			66
Research and development	18,768			19,227
Selling, general and administrative	34,733			35,858
Acquired in-process technology	800			—
Restructuring	13,910			5,371
Total costs and expenses	99,866			89,073
Income (loss) from operations	69,709			(8,638		)
Interest income and other, net	6,872			2,751
Interest expense	(3,589		)	(415		)

Income (loss) before income taxes	72,992			(6,302		)
Income tax (provision) benefit	(26,740		)	2,296
Net income (loss)	$	46,252		$	(4,006	)

Basic net income (loss) per common share	$	0.68		$	(0.06	)
Diluted net income (loss) per common share	$	0.58		$	(0.06	)

Shares used in computing basic net income (loss) per share	68,504			67,905
Shares used in computing diluted net income (loss) per share	83,001			67,905

AFFYMETRIX, INC.

RECONCILIATION OF PRIOR YEAR PRESENTATION TO CURRENT YEAR PRESENTATION

(IN THOUSANDS)

(UNAUDITED)

Prior Year Presentation:

Three Months Ended

March 31, 2007

June 30, 2007

September 30, 2007

December 31, 2007

Product sales

57,807

63,986

69,373

88,617

Product related revenue

13,528

17,167

15,758

11,351

Total product and product related revenue

71,335

81,153

85,131

99,968

Royalties and other revenue

2,422

2,731

9,500

7,034

Revenue from Perlegen Sciences

6,678

4,423

355

590

Total revenue

80,435

88,307

94,986

107,592

Cost of product sales

19,721

23,833

28,082

32,501

Cost of product related revenue

6,475

10,826

7,344

5,166

Cost of revenue from Perlegen Sciences

2,421

1,907

166

274

Total cost of goods sold

28,617

36,566

35,592

37,941

*Adjustments:*

	Three Months Ended
	March 31, 2007		June 30, 2007		September 30, 2007		December 31, 2007
*Revenue*
Product sales (1)	6,678		4,423		355		590
Product related revenue (2)	(13,528	)	(17,167	)	(15,758	)	(11,351	)
Royalties and other revenue (2)	4,771		5,136		4,929		4,895
Revenue from Perlegen Sciences (1)	(6,678	)	(4,423	)	(355	)	(590	)
Services (2)	8,757		12,031		10,829		6,457

COGS
Cost of product sales (3)	2,424		1,893		164		266
Cost of product related revenue (4)	(6,475	)	(10,826	)	(7,344	)	(5,166	)
Cost of revenue from Perlegen Sciences (3)	(2,421	)	(1,907	)	(166	)	(274	)
Cost of services (4)	6,406		10,760		7,307		5,129
Cost of royalties and other revenue (4)	66		80		39		45

Current Year Presentation:

Three Months Ended

March 31, 2007

June 30, 2007

September 30, 2007

December 31, 2007

Product sales

64,485

68,409

69,727

89,207

Services

8,757

12,031

10,829

6,457

Royalties and other revenue

7,193

7,867

14,430

11,928

Total revenue

80,435

88,307

94,986

107,592

Cost of product sales

22,145

25,726

28,246

32,767

Cost of services

6,406

10,760

7,307

5,129

Cost of royalties and other revenue

Total cost of goods sold

28,617

36,566

35,592

37,941

Description of Adjustments:


(1)		To reclassify Revenue from Perlegen Sciences into Product sales

(2)		To reclassify revenue from Product related revenue to Royalties and other revenue and Services

(3)		To reclassify Cost of revenue from Perlegen Sciences into Cost of product sales

(4)		To reclassify Cost of product related revenue to Cost of services and Cost of royalties and other revenue

PREVIOUS SITUATION (for comparing purposes). It seems the turnaround has arrived in force:

September 13, 2006:

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=4383826

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 7, 2006

AFFYMETRIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	0-28218	77-0319159
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3420 Central Expressway
Santa Clara, California 95051

(Address of principal executive offices) (Zip Code)

(408) 731-5000

Registrant’s telephone number, including area code

3420 Central Expressway
Santa Clara, California 95051

(Former name or former address, if changed since last report.)

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 2 - Financial Information

Item 2.05 Costs Associated with Exit or Disposal Activities

On September 7, 2006, Affymetrix, Inc. (the “Company”) committed to a restructuring plan which involves the consolidation and reorganization of its Bedford, Massachusetts based instrumentation manufacturing and development facility. The Company plans to consolidate the Bedford facility’s instrument manufacturing operations with the Company’s probe array manufacturing facility in West Sacramento, California. The Company’s instrumentation development capabilities will be consolidated with its principal research and development facilities located in Santa Clara, California. The restructuring is expected to eliminate or transfer approximately 80 positions beginning in the fourth quarter of 2006 and continuing into the first half of 2007. The Company expects the closure of its Bedford, Massachusetts facility to be materially completed by the third fiscal quarter 2007. These actions were approved as part of the Company’s previously announced efforts to reduce expenses in the general and administrative functions including the rationalization of the Company’s facilities.

The Company expects to incur costs related to this restructuring, including employee related costs and contract termination costs, but as of the date of this Form 8-K, the Company is unable in good faith to make a more precise determination or estimate or range of estimates of costs expected to be incurred in connection with the restructuring in total or for each major type of cost associated with the restructuring, or of the amount of such costs that will result in additional future cash expenditures. The range of costs and other charges the Company expects to incur in connection with this restructuring is subject to a number of assumptions. The Company is currently preparing its analysis of the restructuring costs and expects to complete its analysis before the end of the current fiscal quarter. Accordingly, as permitted by Item 2.05 of Form 8-K, the Company will file an amendment to this report under Item 2.05 within four business days after the Company’s definitive determination of such estimates or range of estimates.

In addition to historical information, this Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. These statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the future results expressed or implied by the forward-looking statements. All statements other than statements of historical facts included in this Current Report on Form 8-K, including statements regarding the Company’s future financial position and results, are forward-looking statements. All information set forth herein is current as of the date of this Current Report on Form 8-K. Except as expressly provided herein, Affymetrix undertakes no duty to update any statement in light of new information or future events. For further information regarding risks and uncertainties associated with Affymetrix’ business, please refer to the “Risk Factors” section of Affymetrix’ SEC filings, including, but not limited to, its annual report on Form 10-K/A for the fiscal year ended December 31, 2005 and subsequent quarterly reports on Form 10-Q and Form 10-Q/A.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AFFYMETRIX, INC.


	By:	/s/ Gregory T. Schiffman
		Name: Gregory T. Schiffman
		Title: Executive Vice President and Chief Financial Officer

Dated: September 13, 2006